P558: GERMAN AMLCG-SURVIVORSHIP STUDY – SOMATIC LONG-TERM CONSEQUENCE OF AML AND ITS THERAPY: FROM HEART TO KIDNEY.

• A. S. Moret,
• E. Telzerow,
• C. Sauerland,
• M. Rothenberg-Thurley,
• F. H. A. Mumm,
• J. Braess,
• B. Wörmann,
• U. Krug,
• W. E. Berdel,
• W. Hiddemann,
• K. Spiekermann,
• P. Heußner,
• K. Kraywinkel,
• D. Görlich,
• K. H. Metzeler

Affiliations

A. S. Moret

1 Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich

E. Telzerow

1 Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich

C. Sauerland

2 Institute of Biostatistics and Clinical Research, University of Münster, Münster

M. Rothenberg-Thurley

1 Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich

F. H. A. Mumm

1 Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich

J. Braess

3 Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg

B. Wörmann

4 Charité University Hospital Berlin, Berlin

U. Krug

5 Department of Medicine 3, Hospital Leverkusen, Leverkusen

W. E. Berdel

6 Department of Medicine A, University of Münster, Münster

W. Hiddemann

1 Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich

K. Spiekermann

1 Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich

P. Heußner

7 Hospital Garmisch-Partenkirchen, Garmisch-Partenkirchen

K. Kraywinkel

8 Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin

D. Görlich

2 Institute of Biostatistics and Clinical Research, University of Münster, Münster

K. H. Metzeler

9 Department of Hematology, Cell Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany